Research epoetin used in patients with anemia

Author: qjyc

August undefined, 2024

WebThe initial clinical use of epoetin was to treat patients with anemia of chronic renal failure, especially patients on dialysis (i.e., end-stage renal disease). Anemia is a deficiency in the concentration of hemoglobin … Webanemia, dyslipidemia, and alcoholic liver disease. e patient had been diagnosed with CKD at the Department of Nephrology, and treated by outpatient care with renal support therapy for the past two years. On X-63 day, his prescription was rosuvastatin (10 mg/day) and a continu-ous erythrocyte-stimulating agent, epoetin beta pegol [7]

Epoetin alfa - Wikipedia

WebEpoetin beta is also effective for the prevention of anaemia and reduction of transfusion requirements in patients with a high risk of developing anaemia during chemotherapy. … WebThe median dose of biosimilar epoetin was 30,000 IU/week during the course of the study. Most patients (99.7%) received biosimilar epoetin via the subcutaneous route, and almost all (98%) received single weekly biosimilar epoetin injections. Results. Use in patients <70 years old vs patients ≥70 years old. Baseline characteristics heiko loyda

IJERPH Free Full-Text Whether Prolyl Hydroxylase …

WebApr 10, 2024 · Akebia Therapeutics shared the research along with findings from another investigation on chronic kidney disease. 2. Patients with hyporesponse to ESAs … WebThis study aimed to investigate the factors associated with resistance to recombinant human erythropoietin therapy with epoetin alfa (αEPO). We performed a prospective, … WebOct 1, 2002 · It is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin for anemic patients … heiko löwenstein katho köln

Anemia & non-dialysis-dependent chronic kidney disease IJNRD

Subcutaneous Compared with Intravenous Epoetin in Patients …

WebAcademia.edu is a platform for academics to share research papers. Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure (PDF) Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure José Martín D Guerrero - … WebDec 30, 2024 · In patients with chronic kidney disease (CKD), anemia develops gradually, which is primarily due to an inadequate synthesis of erythropoietin by the kidneys, as well as to iron disorders in the body, blood loss, shortened erythrocyte survival and inflammation. The currently accepted treatment employs iron, vitamin B12, folic acid supplementation … heiko luchettaWebThe mean baseline Hgb was similar in the two treatment groups: 89 g/L for the ferumoxytol treatment group, compared with 87 g/L for the placebo treatment group. Figure 1 Patient disposition for the subgroup of patients with IDA and GI disorders. Abbreviations: IDA, iron deficiency anemia; GI, gastrointestinal; AE, adverse event. heiko lottermann

"Web1 day ago · Highlights. The global Darbepoetin Alfa market was valued at USD 4904 million in 2024 and is anticipated to reach USD 4010.1 million by 2030, witnessing a CAGR of -2.8 Percent during the forecast ... " - Research epoetin used in patients with anemia

Research epoetin used in patients with anemia

IJERPH Free Full-Text Whether Prolyl Hydroxylase …

WebApr 10, 2024 · Rhabdomyolysis is a potentially life-threatening disease caused by melting or necrosis of skeletal muscle cells and leakage of muscle components into the … WebPurpose/Objectives: To determine the effect of aerobic and strength resistance training and epoetin alfa (EPO) therapy on transfusions, stem cell collections, transplantation recovery, and multiple myeloma treatment response. Design: Randomized clinical trial. Setting: A myeloma research and therapy center in the south central United States.

Did you know?

WebResearch Design Patients (n = 135) ... ESAs in the treatment of anemia for use in patients with ad-vanced breast, head and neck, lymphoid, and non-small cell ... Epoetin alfa for the treatment of cancer- and chemo-therapy-related anaemia: Product … WebNo serious drug-related adverse events were recorded in any of the treatment groups.Conclusion: These data confirm the real-world effectiveness and safety of a biosimilar ESA (Binocrit®) for the treatment of cancer patients with chemotherapy-induced anemia.Keywords: erythropoiesis-stimulating agents, chemotherapy-induced anemia, …

WebEpogen (epoetin alfa) Biosynthetic form of the natural hormone erythropoietin Used for treatment of anemia associated with end-stage renal disease, chemotherapy-induced anemia, and for anemia associated with zidovudine therapy Contraindications: drug allergy, uncontrolled hypertension ( this will increase blood volume, could contraindicate … WebOct 18, 2003 · We investigated whether anaemia correction with epoetin beta could improve outcome of curative radiotherapy among patients with head and neck cancer. Methods: …

WebMar 1, 2024 · This is an ongoing single-center, open-label, external pilot pragmatic randomized controlled trial, since June 2024 in the Kidney Foundation Hospital and Research Institute. The objective is to evaluate the efficacy and safety of Roxadustat compared to Epoetin alfa for treating anemia in maintenance hemodialysis (MHD) patients. WebFeb 1, 1999 · Studies suggest that epoetin alfa is an effective treatment in a proportion of cancer patients with symptomatic anaemia. It also appears useful for the prevention of …

WebJan 12, 2024 · This study aimed to evaluate the difference in patient survival according to the type of erythropoiesis-stimulating agent (ESA) treatment used in the Korean hemodialysis (HD) population. This retrospective study analyzed the laboratory data from a national HD quality assessment program and the claims of Korea. Included participants …

WebFeb 1, 2004 · Treatment with epoetin beta was well tolerated; only 1.4 % patients had thrombotic events. Epoetin beta (30 000 I.U. once weekly) increased Hb levels and was … heiko lubitzWebOct 1, 2002 · The guideline panel found good evidence to recommend use of epoetin as a treatment option for patients with chemotherapy-associated anemia with a hemoglobin … heiko lukasWebEpoetin alfa has the same biological effects as endogenous erythropoietin and is manufactured through recombinant DNA technology. Very few randomized controlled trials have been conducted on the use of this agent except in chronic renal disease patients. Nevertheless, use of epoetin alfa should be considered in severely anemic Jehovah's … heiko luthardtWebNov 16, 2006 · Study finds that high doses of epoetin, drug used to treat anemia in dialysis and cancer patients, may increase risk of heart problems and death; almost a million Americans a year receive ... heiko luikengaWebIn the United States and Europe, chronic hepatitis C infection accounts for 40% of end-stage cirrhosis and 60% of hepatocellular carcinoma. 1 The virus is transmitted through intravenous drug abuse, transfusion of blood, transplantation of organs, occupational exposure to blood, and probably through high-risk sexual behavior. 2 Acute hepatitis C is … heiko luckhardtWebupdate on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol off J Am Soc Clin Oncol. 2010;28(33):4996‐5010. 6. Schrijvers D, De Samblanx H, Roila F, Group EGW. Erythropoiesis‐ stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann Oncol: Off J Eur SocMed heiko lugtWebEpoetin alfa is a drug that is used to treat anaemia caused by illnesses such as chronic renal disease, chemotherapy, and some other conditions. It is also known by the brand name Procrit. Epoetin alfa was recommended to be administered subcutaneously three times per week to the patient in this case, who is 66 years old. It is crucial for a ... heiko luge